accountstudied as a treatment for acute myeloid leukemia that has recurred or not responded to previous treatment. The Food and Drug Administration awarded fast-track status from the Food and Drug Administration in February. The FDA's decision allows Sunesis to...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Sunesis posts 1Q profit on Millennium payment
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account